PureTech Health plc (PRTC)Healthcare | Biotechnology | Boston, United States | NasdaqGM
18.30 USD
+0.08
(0.439%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 18.30 Short-term: ★☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 5, 2026, 1:28 p.m. EDT
PRTC shows a mixed picture with recent price declines and a lack of dividend history. The short-term forecast suggests a slight downward trend, while the long-term outlook is cautiously bearish. The stock's high debt-to-equity ratio and negative forward PE indicate potential financial risks. Investors should consider the company's clinical trial progress and market position before making decisions. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.070718 |
| AutoTheta | 0.087274 |
| MSTL | 0.092339 |
| AutoETS | 0.098284 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 22.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.243 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.326 |
| Revenue per Share | 0.27 |
| Market Cap | 445,455,296 |
| Trailing P/E | 10.76 |
| Forward P/E | -36.60 |
| Beta | 0.71 |
| Profit Margins | 792.96% |
| Website | https://www.puretechhealth.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.093189955 |
| Address1 | 6 Tide Street |
| Address2 | Suite 400 |
| All Time High | 65.9 |
| All Time Low | 13.3 |
| Ask | 15.7 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 4,570 |
| Average Daily Volume3 Month | 3,637 |
| Average Volume | 3,637 |
| Average Volume10Days | 4,570 |
| Beta | 0.714 |
| Bid | 18.7 |
| Bid Size | 1 |
| Book Value | 15.65 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.3 |
| Current Ratio | 8.487 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 18.3714 |
| Day Low | 18.3 |
| Debt To Equity | 44.326 |
| Display Name | PureTech Health |
| Earnings Call Timestamp End | 1,777,467,600 |
| Earnings Call Timestamp Start | 1,777,467,600 |
| Earnings Timestamp | 1,777,465,800 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | -115,718,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -36.485 |
| Enterprise To Revenue | 660.616 |
| Enterprise Value | 4,221,996,544 |
| Eps Forward | -0.5 |
| Eps Trailing Twelve Months | 1.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 482 3337 |
| Fifty Day Average | 16.84078 |
| Fifty Day Average Change | 1.459219 |
| Fifty Day Average Change Percent | 0.08664794 |
| Fifty Two Week Change Percent | 9.318995 |
| Fifty Two Week High | 19.92 |
| Fifty Two Week High Change | -1.6200008 |
| Fifty Two Week High Change Percent | -0.081325345 |
| Fifty Two Week Low | 14.5 |
| Fifty Two Week Low Change | 3.7999992 |
| Fifty Two Week Low Change Percent | 0.26206893 |
| Fifty Two Week Range | 14.5 - 19.92 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,605,537,000,000 |
| Float Shares | 167,373,262 |
| Forward Eps | -0.5 |
| Forward P E | -36.6 |
| Free Cashflow | -160,187,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -48,809,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00393 |
| Implied Shares Outstanding | 24,341,819 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,735,603,200 |
| Long Business Summary | PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. |
| Long Name | PureTech Health plc |
| Market | us_market |
| Market Cap | 445,455,296 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9240598 |
| Most Recent Quarter | 1,751,241,600 |
| Net Income To Common | 50,678,000 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 435,891,111 |
| Open | 18.37 |
| Operating Cashflow | -100,297,000 |
| Operating Margins | -25.895191 |
| Payout Ratio | 0.0 |
| Phone | 617 482 2333 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 18.3 |
| Post Market Time | 1,776,456,026 |
| Previous Close | 18.22 |
| Price Hint | 2 |
| Price To Book | 1.169329 |
| Price To Sales Trailing12 Months | 69.70041 |
| Profit Margins | 7.9295897 |
| Quick Ratio | 8.353 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.07999992 |
| Regular Market Change Percent | 0.43907753 |
| Regular Market Day High | 18.3714 |
| Regular Market Day Low | 18.3 |
| Regular Market Day Range | 18.3 - 18.3714 |
| Regular Market Open | 18.37 |
| Regular Market Previous Close | 18.22 |
| Regular Market Price | 18.3 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 6,059 |
| Return On Assets | -0.1295 |
| Return On Equity | 0.094440006 |
| Revenue Growth | 5.427 |
| Revenue Per Share | 0.27 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,341,819 |
| Shares Percent Shares Out | 0.00059999997 |
| Shares Short | 14,823 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,707 |
| Short Name | PureTech Health plc |
| Short Percent Of Float | 0.0007 |
| Short Ratio | 3.3 |
| Source Interval | 15 |
| State | MA |
| Symbol | PRTC |
| Total Cash | 331,284,000 |
| Total Cash Per Share | 1.379 |
| Total Debt | 163,574,000 |
| Total Revenue | 6,391,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.7 |
| Trailing P E | 10.764705 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.37251 |
| Two Hundred Day Average Change | 0.9274883 |
| Two Hundred Day Average Change Percent | 0.05338827 |
| Type Disp | Equity |
| Volume | 6,059 |
| Website | https://www.puretechhealth.com |
| Zip | 2,210 |